A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Fischer II, William A.
    • Affiliation: School of Medicine, Institute for Global Health and Infectious Diseases
  • Eron Jr, Joseph J.
    • Affiliation: School of Medicine, Department of Medicine
  • Holman, Wayne
    • Other Affiliation: Ridgeback Biotherapeutics LP
  • Cohen, Myron S.
    • Affiliation: School of Medicine, Institute for Global Health and Infectious Diseases
  • Fang, Lei
    • Other Affiliation: Pharstat Inc
  • Szewczyk, Laura J.
    • Other Affiliation: Ridgeback Biotherapeutics LP
  • Sheahan, Timothy P.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Baric, Ralph
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Mollan, Katie R.
    • Affiliation: School of Medicine
  • Wolfe, Cameron R.
    • Other Affiliation: Duke University Medical Center
  • Duke, Elizabeth R.
    • Other Affiliation: University of Washington
  • Azizad, Masoud M.
    • Other Affiliation: Valley Clinical Trials, Inc.
  • Borroto-Esoda, Katyna
    • Other Affiliation: KBE Consulting
  • Wohl, David A.
    • Affiliation: School of Medicine, Institute for Global Health and Infectious Diseases
  • Coombs, Robert W.
    • Other Affiliation: University of Washington
  • Loftis, Amy James
    • Affiliation: School of Medicine, Institute for Global Health and Infectious Diseases
  • Alabanza, Paul
    • Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Lipansky, Felicia
    • Other Affiliation: Ridgeback Biotherapeutics LP
  • Painter, Wendy P.
    • Other Affiliation: Ridgeback Biotherapeutics LP
Abstract
  • Molnupiravir (800 mg dose) accelerated SARS-CoV-2 RNA clearance in patients with COVID-19 compared to placebo.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 3.0 United States
Journal title
  • Science Translational Medicine
Language
  • English
Version
  • Publisher

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details scitranslmed.abl7430.pdf 2022-01-03 Public Download